Navigation Links
True blood: SLU scientist investigates clotting factors

ST. LOUIS -- Alireza "Ray" Rezaie, Ph.D., professor of biochemistry and molecular biology at Saint Louis University School of Medicine, has received a $1.52 million NIH grant to study how the key blood clotting inhibitor antithrombin might be exploited to prevent premature death from heart disease.

The National Heart Lung and Blood Institute awarded the four-year grant, which will allow Rezaie to continue studying how to maintain the delicate balance between the life-preserving and life-threatening activity of blood clotting.

"Blood clotting factors must be turned on and off at exactly the right time so a person does not bleed to death or die of an episode such as a heart attack, which is triggered by a blood clot," said Rezaie, who has engineered molecules that impose equilibrium on the delicate system.

Rezaie recently discovered that antithrombin, which is a molecule produced by the liver that turns off several proteins in the coagulation system, can block inflammation in the blood vessel wall. This inflammation can lead to heart disease as well as a violent, life-threatening reaction to blood infections called acute sepsis.

Rezaie is working on harnessing the anti-inflammatory activity of antithrombin to reduce the incidence and severity of heart disease and to save the lives of those who suffer from acute sepsis. He has studied the control of blood clotting factors for 23 years.

Blood carries nutrients and oxygen to the body's organs and tissues as well as the ordnance of immunityantibodies and white blood cellsthat defend organs and tissues from infection. Given these critical functions, it is essential that bodies preserve blood against loss from bleeding injuries.

Imbedded in blood is the chemistry to stop bleeding before too much blood is lost. Whenever small cuts or bruises occur, the blood at the site of injury rapidly mobilizes clotting factors that build a plug at the breech in the blood vessel to prevent blood loss.

However, the ability to make blood clot is also the cause of vascular disease and sudden death for some when it is not controlled properly.

Efficient blood clotting can be a double-edged sword when clots appear at the wrong places and times. Heart attack, stroke and pulmonary embolism are life-threatening conditions stemming from clots that block blood circulation to the heart, brain or lung.

Currently, a patient who suffers a heart attack, stroke or pulmonary embolism is treated with heparin, a medication that prevents the formation of additional life-threatening blood clots. At the same time, heparin treatment puts patients at risk of uncontrolled bleeding by inhibiting antithrombin, which upsets the body's normal response to injury and infections.

"The blood clotting cascade has to be maintained in a balanced state not too much of one and not too little of the other," Rezaie said.

In parallel with his pioneering work on antithrombin, Rezaie is also working to improve the anticoagulant activated protein C. This FDA-approved vitamin K-dependent blood clotting factor has been used to treat acute sepsis in adults, which affects nearly 750,000 Americans annually and results in at least 225,000 deaths.

His ongoing studies on activated protein C are funded by another $1.5 million grant from the National Institutes of Health, given in 2010. They aim to improve the ability of the protein to prevent organ failure while reducing its anti-clotting activity, so that bleeding complications can be avoided.

Rezaie's work builds on the legacy of Edward A. Doisy, Ph.D., the first chair of SLU's department of biochemistry and molecular biology, who received a Nobel prize in 1943 for determining the chemical nature of vitamin K, which is an essential component in blood coagulation.

"I am working with the blood clotting factors that are activated by Dr. Doisy's vitamin K, which does something to these molecules so they can physiologically function," Rezaie said.


Contact: Nancy Solomon
Saint Louis University

Related biology news :

1. Scientists join forces in call for action to save coral reefs
2. Scientists discover an epigenetic cause of osteoarthritis
3. New York University scientists discover possible treatment to reduce scarring
4. Scientists discover new trigger for immense North Atlantic plankton bloom
5. Atmospheric scientists release first bottom-up estimates of Chinas CO2 emissions
6. Stanford scientists find molecule to starve lung cancer and improve ventilator recovery
7. Scripps Florida scientists identify critical quality control for cell growth
8. Gladstone scientists identify critical process in stem cell development
9. Wholly water -- students and scientists gather at NTU to discuss water problem
10. Cancer scientists link ‘oncometabolite’ to onset of acute myeloid leukemia
11. Rensselaer scientists unlock some key secrets of photosynthesis
Post Your Comments:
Related Image:
True blood: SLU scientist investigates clotting factors
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight ... solutions to the healthcare market. The company's primary focus is on new product ... marketing strategies that are necessary to help companies efficiently bring their products to ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology: